Kuwait

The primary regulatory authority overseeing health products in Kuwait is the Kuwait Drug and Food Control Authority (KDFCA), operating under the Ministry of Health (MOH). Health product regulation in Kuwait is governed by Law No. 48 of 1967 and its subsequent amendments, along with ministerial decrees that address pharmaceuticals, medical devices, diagnostics, and increasingly, digital health solutions. All health products intended for the Kuwaiti market must obtain formal registration or approval from the KDFCA before they can be marketed, imported, or distributed. The general approval process involves product dossier submission, technical evaluation by KDFCA committees, laboratory testing where applicable, and final issuance of a registration certificate. Kuwait also participates in the Gulf Cooperation Council (GCC) harmonization framework, meaning that approvals granted through the GCC Central Registration Committee (CRC) can facilitate streamlined registration across member states, including Kuwait.

Applicants seeking market authorization in Kuwait are required to appoint a locally registered agent or authorized representative based in Kuwait, as foreign manufacturers cannot register products directly. Submissions are generally expected to conform to Common Technical Document (CTD) format for pharmaceuticals, and for medical devices, Kuwait references GCC technical regulations that align with international standards such as ISO 13485 and GHTF/IMDRF guidelines. Supporting documentation typically includes certificates of conformity, CE marking or equivalent international certification, free sale certificates from the country of origin, and Good Manufacturing Practice (GMP) certificates. In recent years, Kuwait has undertaken reforms to digitize submission processes through the KDFCA's online portal and has strengthened post-market surveillance requirements. The country has also moved toward aligning its regulatory frameworks more closely with GCC-wide harmonization initiatives, reducing duplication of effort for manufacturers registered elsewhere in the Gulf region.

Public procurement of health products in Kuwait is highly centralized and dominated by the Ministry of Health (MOH), which is responsible for purchasing and distributing pharmaceuticals, medical devices, diagnostics, and health technologies for the public sector. The Central Tenders Committee (CTC), established under Law No. 37 of 1964, is the principal government body managing public tenders, including those for health-related goods and services. Large-scale health product procurement is conducted through open or selective international tenders, with contracts awarded based on technical specifications, pricing, and compliance with regulatory requirements. The MOH maintains a list of approved and registered products, and only products with valid KDFCA registration are eligible for inclusion in public tenders. Procurement planning is typically aligned with the national health budget cycle, and framework agreements may be used for high-volume or recurring consumable needs. Local agents and distributors play a critical role in the public procurement process, as they are the contracting counterparts to the government on behalf of foreign manufacturers.

The private healthcare sector in Kuwait is growing steadily, driven by government incentives to attract private investment and reduce pressure on public facilities. Private hospitals, clinics, and pharmacies source health products through licensed local distributors and importers, often independently of the MOH procurement system, though all products must still carry valid KDFCA registration. Kuwait is a high-income country and does not typically receive procurement support from international donor organizations such as UNICEF Supply Division, the Global Fund, Gavi, or USAID; its health procurement is almost entirely self-funded through state revenues. However, Kuwait occasionally engages with international health organizations for technical assistance and capacity building rather than product financing. There is a nascent interest in encouraging local manufacturing and partnerships within the GCC industrial strategy framework, with some preference signals for GCC-origin products in tender evaluations, though explicit local content mandates remain limited compared to some other regional markets.